IIM
HRMY icon

Illumine Investment Management’s Harmony Biosciences HRMY Stock Holding History

Illumine Investment Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$680K Buy
24,277
+1,032
+4% +$33.8K 0.52% 68
2025
Q4 		$870K Buy
23,245
+878
+4% +$28.9K 0.63% 53
2025
Q3 		$616K Buy
22,367
+976
+5% +$33.6K 0.44% 69
2025
Q2 		$676K Buy
+21,391
New +$688K 0.54% 61

Other funds holding HRMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Illumine Investment Management's HRMY Position: Q1 2026 in Review

Illumine Investment Management increased its Harmony Biosciences (HRMY) stake by 4.4% in Q1 2026, buying an estimated $33.8K and bringing the position to 24,277 shares worth $680K. The position accounts for 0.52% of the portfolio, ranked #68.

Illumine Investment Management first reported a position in HRMY in Q2 2025 and has held it in 4 quarters since. The position peaked at $870K in Q4 2025. 309 funds tracked by Wall St. Rank hold HRMY as of Q1 2026.

  • Illumine Investment Management held 24,277 shares of Harmony Biosciences worth $680K as of Q1 2026.
  • Illumine Investment Management bought 1,032 Harmony Biosciences shares in Q1 2026, an estimated $33.8K.
  • Harmony Biosciences made up 0.52% of Illumine Investment Management's portfolio in Q1 2026, its #68 holding.
  • Illumine Investment Management first reported a position in Harmony Biosciences in Q2 2025 and has held it in 4 quarters since.
  • Illumine Investment Management's Harmony Biosciences position peaked at $870K in Q4 2025.
  • 309 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2026.

Based on Illumine Investment Management's 13F filing for Q1 2026, filed 4 May 2026.